Gapping down
In reaction to disappointing earnings/guidance:
- HCSG -19.5%, EXTR -15.5%, FTR -14.4%, CAMP -11%, MGPI -9.5%, SSNC -7.8%, HVT -7.6%, CYH -7%, WATT -6.1%, CAI -5.6%, LXRX -4.5%, FEYE -3.4%, OLN -3.3%, CHRW -3.2%, ENLC -3.1%, ASH -3.1%, CLX -3%, TENB -2.5%, CSTE -2.5%, YUM -2.3%, ZEN -2.2%, EXAS -2%, AX -1.8%, VNOM -1.7%, APY -1.7%, TAP -1.6%, NBR -1.4%, AMRN -1.1%, VRTX -0.9%, ENBL -0.9%, SO -0.9%, AMGN -0.8%, AME -0.8%
Other news:
- NBRV -23.7% (receives Complete Response Letter from FDA on NDA for Intravenous CONTEPO)
- TBIO -7.3% (entered into a securities purchase agreement with several institutional accredited investors for the private placement of 5,582,940 shares of common stock at $8.50/share)
- NBEV -3.1% (entered into $100 mln at the market offering agreement)
- KRP -1.9% (attributed to block trade pricing)
- RGEN -1.7% (prices underwritten public offering of 2,734,375 shares of common stock at $64.00 per share)
- DSSI -1.1% (files 11.68 mln share common share offering by selling shareholders)
- WAB -1% (announces secondary public offering of 12.5 mln shares of common stock by selling stockholder; also files for 47,833,671 share common stock shelf offering by holders - includes ~28 mln shares issuable upon conversion of Series A non-voting convertible preferred stock)
Analyst comments:
- N/A.